Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–9.
   PubMed Web of Science ®Google Scholar
• Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-term survivors of pancreatic cancer: a California population-based study. Pancreas. 2018;47:958.
   PubMed Web of Science ®Google Scholar
• Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes & Control. 2006;17:403–409.
   PubMed Web of Science ®Google Scholar
• Lee KIMJE. KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical Usefulness of Carbohydrate Antigen 19-9 as a Screening Test for Pancreatic Cancer in an Asymptomatic Population Journal of Gastroenterology and Hepatology. 2004;19:182–186.
   Google Scholar
• Tong Y, Song Z, Zhu W. Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China. Clinical Chemistry and Laboratory Medicine (CCLM). 2013;51:1459–1466.
   Google Scholar
• Greer JB, Whitcomb DC. Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol. 2009;9:411–418.
   PubMed Web of Science ®Google Scholar
• Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman L, Lin J, Sun Y, Rech A, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity. 2018;49(1):93–178. e7.
   PubMed Web of Science ®Google Scholar
• Luo D, Kuang F, Du J, Zhou M, Peng F, Gan Y, Fang C, Yang X, Li B, Su S, et al. Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy. Front Oncol. 2021;11:1614.
   Web of Science ®Google Scholar
• Yako YY, Kruger D, Smith M, Brand M. Cytokines as biomarkers of pancreatic ductal adenocarcinoma: a systematic review. PloS One. 2016;11:e0154016.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zou M, Wen X, Gu F, Li J, Liu G, Dong J, Deng X, Gao J, Li X, et al. Development of serum parameters panels for the early detection of pancreatic cancer. Int J of Cancer. 2014;134(11):2646–2655.
   PubMed Web of Science ®Google Scholar
• Mroczko B, Groblewska M, Gryko M, Kędra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL‐6) and C‐reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal. 2010;24:256–261.
   PubMed Web of Science ®Google Scholar
• Thiele M, Kerschbaumer RJ, Tam FW, Völkel D, Douillard P, Schinagl A, Kuehnel H, Smith J, McDaid JP, Bhangal G, et al. Selective targeting of a disease-related conformational isoform of macrophage migration inhibitory factor ameliorates inflammatory conditions. The J of Immunology. 2015;195(5):2343–2352.
   PubMed Web of Science ®Google Scholar
• Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.
   PubMed Web of Science ®Google Scholar
• Takano K, Sakata J, Hirose Y, Miura K, Ichikawa H, Nagahashi M, Shimada Y, Kameyama H, Kobayashi T, Wakai T, et al. Macrophage migration inhibitory factor expression predicts clinical outcomes in patients with resected pancreatic ductal adenocarcinoma. HPB. 2019;21:S424–S5.
   Google Scholar
• Wang D, Wang R, Huang A, Fang Z, Wang K, He M, Yia J, Li W. Upregulation of macrophage migration inhibitory factor promotes tumor metastasis and correlates with poor prognosis of pancreatic ductal adenocarcinoma. Oncol Rep. 2018;40(5):2628–2636.
   PubMed Web of Science ®Google Scholar
• Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer. 2005;5:1–12.
   PubMed Web of Science ®Google Scholar
• Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, et al. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J of Cancer. 2013;132(4):785–794.
   PubMed Web of Science ®Google Scholar
• Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, Sugimachi K. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clinical Cancer Research. 2002;8:3755–3760.
   PubMed Web of Science ®Google Scholar
• Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–1474.
   PubMed Web of Science ®Google Scholar
• Halama N, Spille A, Lerchl T, Brand K, Herpel E, Welte S, Keim S, Lahrmann B, Klupp F, Kahlert C, et al. Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. Oncoimmunology. 2013;2(4):e24116.
   PubMed Web of Science ®Google Scholar
• Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell. 2016;29(4):587–601.
   PubMed Web of Science ®Google Scholar
• Halama N, Zoernig I, Spille A, Westphal K, Schirmacher P, Jaeger D, Grabe N. Estimation of immune cell densities in immune cell conglomerates: an approach for high-throughput quantification.PloS One. 2009;4(11):e7847.
   Google Scholar
• Halama N, Zoernig I, Spille A, Michel S, Kloor M, Grauling-Halama S, Westphal K, Schirmacher P, Jaeger D, Grabe N. Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps. Anal Quant Cytol Histol. 2010;32(6):333–340.
   Google Scholar
• Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 2011;17(4):678–689.
   Google Scholar
• Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. New England J of Medicine. 2006;354:610–621.
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–820.
   PubMed Web of Science ®Google Scholar
• Mack CL. Serum cytokines as biomarkers of disease and clues to pathogenesis. Hepatology. 2007;46(1):6-8.
   Google Scholar
• Owen DL, Mahmud SA, Vang KB, Kelly RM, Blazar BR, Smith KA, Farrar MA. Identification of cellular sources of IL-2 needed for regulatory T cell development and homeostasis. The J of Immunology. 2018;200(12):3926–3933.
   PubMed Web of Science ®Google Scholar
• Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017;18:851–860.
   PubMed Web of Science ®Google Scholar
• Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, Ter Horst R, Jansen T, Jacobs L, Bonder MJ, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167(4):36–1125. e8.
   Web of Science ®Google Scholar
• Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Lackner C, Ress AL, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 2014;110(1):183–188.
   PubMed Web of Science ®Google Scholar
• Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36:763–777.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5:e1163462.
   PubMed Web of Science ®Google Scholar
• Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castanón E, Melero I, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15.
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW, Mitchell RA. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. The J of Immunology. 2013;190(6):2984–2993.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10:1–12.
   PubMed Web of Science ®Google Scholar
• Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914–923.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Voelkel D, Youssef A, de Jong FA, et al. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol. 2020;86(9):1836–1848.
   PubMed Web of Science ®Google Scholar